These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34093040)

  • 1. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer.
    Zhang L; Li N; Liu M; Zheng B; Wu Z; Cai H
    Cancer Manag Res; 2021; 13():4263-4270. PubMed ID: 34093040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
    Xu X; Fang N; Li H; Liu Y; Yang F; Li X
    Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.
    Yu YF; Luan L; Zhu FF; Dong P; Ma LH; Li LT; Gao L; Lu S
    Front Oncol; 2021; 11():564234. PubMed ID: 34970476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Cortijo J
    J Comp Eff Res; 2021 Mar; 10(4):325-335. PubMed ID: 33635095
    [No Abstract]   [Full Text] [Related]  

  • 5. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
    Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
    Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.
    Guan H; Wang C; Chen C; Han S; Zhao Z
    Front Oncol; 2022; 12():819674. PubMed ID: 35785198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
    Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
    Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
    Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
    PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.
    Li J; Nickens D; Wilner K; Tan W
    Oncol Ther; 2021 Dec; 9(2):525-539. PubMed ID: 34120312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
    Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
    Chouaid C; Luciani L; LeLay K; Do P; Bennouna J; Perol M; Moro-Sibilot D; Vergnenègre A; de Pouvourville G
    J Thorac Oncol; 2017 Oct; 12(10):1496-1502. PubMed ID: 28751244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy in patients with
    Pu X; Li J; Zhang B; Zhang J; K Mok TS; Nakagawa K; Rosell R; Cheng Y; Zhou X; Miglorino MR; Niho S; Lee KH; Corral J; Pluzanski A; Li J; Linke R; Pan F; Tang Y; Tan W; Wu L
    Future Oncol; 2024; 20(37):2971-2982. PubMed ID: 39360943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.